secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001493152-25-021749
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics regains NYSE compliance, raises $16.5M, partners with Receptor.AI, advances Phase IIa trial
--------------------------------------------------------------------------------

- Regained NYSE American compliance on Oct 20, 2025, resolving equity deficiency and removing below-compliance indicator.
- Completed $16.5M gross capital raise via Series H Convertible Preferred Stock in July 2025; net proceeds ~$15.2M.
- Eliminated $3M note payable and restored stockholder equity above the $6M NYSE threshold.
- Formed strategic collaboration with Receptor.AI to use AI-driven discovery for pipeline beyond concussion.
- Anticipates Phase IIa trial initiation for ONP-002 in Q4 2025/Q1 2026 in Australia, with U.S. Phase IIb planning underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000149315225021749/0001493152-25-021749-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000149315225021749/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-021749

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer